BVAXF (BioVaxys Technology) Common Stock : $19.64 Mil (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Common Stock?

BioVaxys Technology's quarterly common stock increased from Jul. 2024 ($19.05 Mil) to Oct. 2024 ($19.66 Mil) but then declined from Oct. 2024 ($19.66 Mil) to Jan. 2025 ($19.64 Mil).

BioVaxys Technology's annual common stock increased from Oct. 2022 ($12.46 Mil) to Oct. 2023 ($16.04 Mil) and increased from Oct. 2023 ($16.04 Mil) to Oct. 2024 ($19.66 Mil).

BioVaxys Technology Common Stock Historical Data

The historical data trend for BioVaxys Technology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Common Stock Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Common Stock

Get a 7-Day Free Trial

8.13

11.87

12.46

16.04

19.66

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Common Stock	Get a 7-Day Free Trial															17.40	17.66	19.05	19.66	19.64

BioVaxys Technology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.